Dysregulation and activation of upstream effectors of the PI3K signaling pathway, such as RTKs and Ras mutations, or specific gene amplification and activating mutations in the PI3K alpha catalytic sub-unit (PIK3CA), as well as functional loss of PTEN, are all events frequently observed in many different cancer types [5]. This evidence concerns the gene PIK3CA and cancer.